search
Back to results

Hemodynamic Optimization By Non-Invasive Determination Of Cardiac Output In Critically Ill Patients

Primary Purpose

Hypotension

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
USCOM-guided fluid administration
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypotension focused on measuring Hypotension, Fluid

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 yrs or greater
  • Administration of vasopressors, defined as a continuous infusion of norepinephrine at a dose >5 mcg/min, dopamine ≥5 mcg/kg/min or any dose of another vasopressor
  • Passage of <18 hours since initiation of vasopressors at doses specified above

Exclusion Criteria:

  • Hemorrhagic shock
  • Need for immediate surgery
  • Imminent risk of death in the next 48 hours (as judged by the attending ICU physician)
  • Level of care decision that precluded implementation of the study protocol
  • Enrollment in any other clinical study
  • Pregnancy

Sites / Locations

  • Barnes-Jewish Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control

USCOM

Arm Description

No measurements are made on the control group.

Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.

Outcomes

Primary Outcome Measures

Time on vasopressors, measured during the 48 hours after study enrollment

Secondary Outcome Measures

ICU length of stay
Hospital length of stay
Duration of mechanical ventilation
Development of acute renal failure
Invasive procedures performed after study enrollment
Intravenous fluids infused in first 2 hours after enrollment
Intravenous fluids infused in first 48 hours after enrollment
Need for hemodialysis

Full Information

First Posted
March 2, 2011
Last Updated
March 3, 2011
Sponsor
Washington University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT01309724
Brief Title
Hemodynamic Optimization By Non-Invasive Determination Of Cardiac Output In Critically Ill Patients
Official Title
HEMODYNAMIC OPTIMIZATION BY NON-INVASIVE DETERMINATION OF CARDIAC OUTPUT IN CRITICALLY ILL PATIENTS: A RANDOMIZED, CONTROLLED TRIAL
Study Type
Interventional

2. Study Status

Record Verification Date
March 2011
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Washington University School of Medicine

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Inadequate identification of and subsequent delayed therapy for patients with hypoperfusion (including hypovolemia, congestive heart failure and sepsis) is a common problem faced by physicians and intensivists caring for critically ill patients. Bedside clinical assessment is notoriously inaccurate in diagnosing complex etiologies of hemodynamic disturbances and in deciding on the appropriate therapy. Invasive techniques which are often required to guide diagnosis and therapy have significant risks associated with them, are costly, and are time consuming. New technology has been developed that allows for instantaneous, noninvasive monitoring of key hemodynamic parameters, like stroke volume, peak velocity and cardiac output. This new technology has the potential to improve recognition of the etiology of hemodynamic disturbances and assist the clinician in optimizing therapy based on changes in hemodynamic parameters. There is significant potential for this to be translated into improved outcomes in critically ill patients, but this has never been studied.
Detailed Description
Patients with life-threatening hypotension are commonly cared for in intensive care units (ICUs). Pathophysiologic perturbations due to disease states such as sepsis, hypovolemia, and congestive heart failure may lead to tissue hypoxia, a critical development which precedes multi-organ failure and death. Not only is it difficult to rapidly identify patients heading down this path, but the execution of effective hemodynamic resuscitation to slow or reverse this process is challenging. A cornerstone of hemodynamic resuscitation is volume administration. The goal of volume administration is to maximize cardiac output, and thereby systemic oxygen delivery, by optimizing cardiac preload. Bedside clinical assessment is inadequate for judging whether or not this goal has been achieved. Invasive techniques, such as central venous pressure (CVP) monitoring and pulmonary artery catheterization, carry risks, are costly and time-consuming, and may yield misleading data. Doppler ultrasound-based technology has been developed that allows for instantaneous, non-invasive monitoring of key hemodynamic parameters, such as cardiac output. This technology may facilitate determining the etiology of hemodynamic disturbances and assist the clinician in optimizing therapy based on changes in hemodynamic parameters. This randomized, controlled trial was designed to determine the impact of a volume resuscitation protocol, guided by non-invasive Doppler ultrasound technology, on outcomes in medical ICU patients with vasopressor-dependent hypotension. Materials and methods: Patient Population: Study participants were recruited between January 19, 2010 and December 26, 2010 from two medical ICUs at Barnes-Jewish Hospital, a 1252-bed urban teaching hospital. The Washington University School of Medicine Human Research Protection Office approved the study, and informed consent was obtained from participants or their authorized representatives. Inclusion criteria were age ≥18 years; administration of vasopressors, defined as a continuous infusion of norepinephrine at a dose >5 mcg/min, dopamine ≥5 mcg/kg/min or any dose of another vasopressor; and passage of <18 hours since initiation of vasopressors at doses specified above. Exclusion criteria were hemorrhagic shock, need for immediate surgery, imminent risk of death in the next 48 hours (as judged by the attending ICU physician), level of care decision that precluded implementation of the study protocol, enrollment in any other clinical study, and pregnancy. Study Protocol: Subjects were assigned to treatment groups using blocked randomization to receive either volume resuscitation guided by the ultrasound cardiac output monitor (USCOM; USCOM Ltd., Sydney, Australia) or observation. The USCOM is a non-invasive device that uses continuous-wave Doppler ultrasound measurements of blood flow in the ascending aorta or pulmonary artery to estimate stroke volume (SV). Prior to the beginning of the study, one of the study investigators (LMD) underwent a supervised training period with the USCOM in 50 patients to insure reproducibility of the obtained measurements. Subjects randomized to the intervention group underwent a baseline USCOM measurement of SV by a single operator (LMD), followed by a pressurized infusion of 1 L of normal saline (NS) over approximately 15 minutes, after which the SV measurement was repeated. If the SV increased by ≥15%, the patient was deemed volume-responsive, and another 1 L NS bolus was administered. This process was repeated until the SV did not increase by ≥15%, two hours had elapsed since study enrollment, or 4 L of NS had been infused, whichever occurred first. With the exception of initial fluid management in the intervention group, as described above, use of all diagnostic and treatment modalities were at the discretion of the ICU physicians. Subjects in the control group underwent no intervention; ongoing care was carried out at the discretion of the ICU physicians. ICU physicians were unaware of subjects' group assignments and the USCOM data acquired in the intervention group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypotension
Keywords
Hypotension, Fluid

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
92 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
No measurements are made on the control group.
Arm Title
USCOM
Arm Type
Experimental
Arm Description
Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.
Intervention Type
Other
Intervention Name(s)
USCOM-guided fluid administration
Other Intervention Name(s)
Ultrasound cardiac output monitor
Intervention Description
Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
Primary Outcome Measure Information:
Title
Time on vasopressors, measured during the 48 hours after study enrollment
Time Frame
48 hours after study enrollment
Secondary Outcome Measure Information:
Title
ICU length of stay
Time Frame
At one month (average)
Title
Hospital length of stay
Time Frame
At one month (average)
Title
Duration of mechanical ventilation
Time Frame
At one month (average)
Title
Development of acute renal failure
Time Frame
At one month (average)
Title
Invasive procedures performed after study enrollment
Time Frame
At one month (average)
Title
Intravenous fluids infused in first 2 hours after enrollment
Time Frame
First 2 hours after study enrollment
Title
Intravenous fluids infused in first 48 hours after enrollment
Time Frame
First 48 hours after study enrollment
Title
Need for hemodialysis
Time Frame
At one month (average)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 yrs or greater Administration of vasopressors, defined as a continuous infusion of norepinephrine at a dose >5 mcg/min, dopamine ≥5 mcg/kg/min or any dose of another vasopressor Passage of <18 hours since initiation of vasopressors at doses specified above Exclusion Criteria: Hemorrhagic shock Need for immediate surgery Imminent risk of death in the next 48 hours (as judged by the attending ICU physician) Level of care decision that precluded implementation of the study protocol Enrollment in any other clinical study Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lee M Demertzis, MD
Organizational Affiliation
Barnes-Jewish Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marin H Kollef, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Warren Isakow, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Study Director
Facility Information:
Facility Name
Barnes-Jewish Hospital
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Hemodynamic Optimization By Non-Invasive Determination Of Cardiac Output In Critically Ill Patients

We'll reach out to this number within 24 hrs